Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.

Kim, Dongsung; Xue, Jenny Yaohua; Lito, Piro

Kim, Dongsung; Xue, Jenny Yaohua; Lito, Piro.

Affiliation

Kim D; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA.
Xue JY; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.
Lito P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY, USA; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: litop@mskcc.org.

Cell ; 183(4): 850-859, 2020 11 12.

Article in En | MEDLINE | ID: mdl-33065029

Subject(s)

Antineoplastic Agents/pharmacology; Molecular Targeted Therapy; Mutation/genetics; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors; Proto-Oncogene Proteins p21(ras)/genetics; Clinical Trials as Topic; Drug Resistance, Neoplasm/drug effects; Humans

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Proto-Oncogene Proteins p21(ras) / Molecular Targeted Therapy / Mutation / Antineoplastic Agents Limits: Humans Language: En Journal: Cell Year: 2020 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google